NCT04537156 2025-11-21
Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
Xiamen University
Phase 3 Active not recruiting
Clinical Trials
7 trialsNCT06866574 2025-07-31
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
Xiamen University
Phase 3 Active not recruiting
NCT05056402 2025-07-22
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
Xiamen University
Phase 3 Active not recruiting
NCT06454175 2025-01-06
A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years
Shanghai Bovax Biotechnology Co., Ltd.
Phase 1 Active not recruiting
NCT06465914 2024-12-12
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Active not recruiting
NCT05314023 2023-01-19
V503-053
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05662020 2022-12-27
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
Beijing Health Guard Biotechnology, Inc
Phase 3 Active not recruiting